The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Dexmedetomidine Hydrochloride in 0.9 per cent sodium chloride injection, 200 µg/50 mL and 400 µg/100 mL single dose flexible containers (bags), Aurobindo Pharma said in a regulatory filing.Aurobindo Pharma gets USFDA nod for sedative drug
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Dexmedetomidine Hydrochloride in 0.9 per cent sodium chloride injection, 200 µg/50 mL and 400 µg/100 mL single dose flexible containers (bags), Aurobindo Pharma said in a regulatory filing.
Subscribe to:
Post Comments (Atom)
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment